Taken together, simultaneous targeting of STAT3 and the PI3K/mTOR pathway can sensitize PTEN-deficient cancer cells to BEZ235, and inhibit tumor growth in vivo (Fig. 6D). This evidence concerns the gene PIK3CA and neoplasm.